This week in Nordic in brief: Drug firm axes 1,200 researchers; Norway faces PhD drought; Permafrost centre tackles Greenland climate change; Sweden boosts innovation ‘bridges’; Novozymes takes to the catwalk.
Drug firm axes 1,200 researchers
Astra Zeneca has announced it is making 1,200 researchers redundant in Södertälje, south of Stockholm, to cut costs. The clinical research in Södertälje focuses on treatments for depression and schizophrenia and is to be taken on by a virtual research group of 40 to 50 researchers working in Boston in the US and Cambridge in the UK. The virtual group, known as iMed, will work closely with partners such as the Karolinska Institute in Stockholm, the company said.